Victor Nunez, MD
Infectious Disease · Marietta, GANPI 1457446049
Payments from drug & device makers
Across 370 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- Insmed, Inc.$775
- Merck$655
- AbbVie$653
- Melinta Therapeutics, LLC$423
- plus $2K from 26 others
What the payments were for
- Food & beverage$7,67599%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 82 | $1,537 |
| Gilead | 67 | $1,486 |
| Insmed, Inc. | 33 | $775 |
| Merck | 31 | $655 |
| AbbVie(2 entities) | 33 | $653 |
| Melinta Therapeutics, LLC | 21 | $423 |
| La Jolla Pharmaceutical Company | 9 | $209 |
| Shionogi Inc | 9 | $200 |
| Johnson & Johnson | 12 | $197 |
| Theratechnologies Inc. | 11 | $197 |
| Aimmune Therapeutics, Inc. | 7 | $161 |
| Tetraphase Pharmaceuticals, Inc. | 7 | $150 |
| Paratek Pharmaceuticals, Inc. | 6 | $115 |
| Angiodynamics, Inc. | 2 | $109 |
| Astellas Pharma US Inc | 4 | $92 |
| Pfizer | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| CSL Behring | 3 | $70 |
| Nabriva Therapeutics, PLC | 3 | $59 |
| Grifols USA, LLC | 3 | $58 |
| EMD Serono, Inc. | 3 | $55 |
| Mylan Pharmaceuticals Inc. | 2 | $52 |
| Teleflex LLC | 2 | $49 |
| Shire North American Group Inc | 2 | $48 |
| Dynavax Technologies Corporation | 3 | $46 |
| Ferring Pharmaceuticals Inc. | 2 | $37 |
| Cormedix Inc. | 1 | $34 |
| X4 Pharmaceuticals, Inc. | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Napo Pharmaceuticals Inc | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $12 |
How this compares
$7,724 in reported general payments places this provider in the 70th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 65 | $315,270 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 17 | $265,182 |
| DovatoDolutegravir Sodium/Lamivudine | 40 | $120,584 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 19 | $78,779 |
| PrezcobixDarunavir/Cobicistat | 29 | $69,716 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 15 | $65,211 |
| JulucaDolutegravir/Rilpivirine | 14 | $54,818 |
| DescovyEmtricitabine/Tenofov Alafenam | 21 | $46,103 |
| IsentressRaltegravir Potassium | 20 | $38,388 |
| TivicayDolutegravir Sodium | 12 | $29,503 |
| Rifabutin | 11 | $7,714 |
| Cefepime Hcl | 23 | $7,138 |
| Daptomycin | 23 | $6,424 |
| CeftriaxoneCeftriaxone Sodium | 30 | $3,148 |
| Ethambutol Hcl | 32 | $2,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,486 | $426,584101 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Juluca, Tivicay | $1,537 | $283,68485 claims |
| Insmed, Inc.Arikayce | $775 | $265,18217 claims |
| Johnson & JohnsonPrezcobix | $197 | $69,71629 claims |
| MerckIsentress | $655 | $38,38820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Marietta
- Danny BranstetterMarietta$367K
- Neha ParanjapeMarietta$158K
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
- Jeffrey StephensMacon$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.